

Ref. No: FOI2554
Date: 06/05/2026
Subject: Treatment of inflammatory diseases

REQUEST

Q1 - How many patients were treated by individual drug for Plaque Psoriasis and Psoriatic Arthritis for the three-month period specified within Q1a?.

Q1a – How many patients were treated with the following drugs for the following diseases from the start of January 2026 to the end of March 2026?
Please use the latest available 3 months if January to March is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Drug Name	Plaque psoriasis	Psoriatic arthritis
Adalimumab		
Apremilast		
Bimekizumab		
Brodalumab		0
Certolizumab Pegol		
Deucravacitinib		0
Etanercept		
Etrasimod	0	0
Filgotinib	0	0
Golimumab	0	
Guselkumab		
Infliximab (Biosimilars)		
Infliximab (Remicade)		
Ixekizumab		
Mirikizumab	0	0
Ozanimod	0	0
Risankizumab		
Secukinumab		
Tildrakizumab		0
Tofacitinib	0	
Upadacitinib	0	
Ustekinumab		

Vedolizumab	0	0
-------------	---	---

e

Q2a – How many patients were treated with the following drugs from the following departments (for any disease) from the start of January 2026 to the end of March 2026?

Please use the latest available 3 months if January to March is not available and specify which 3 months has been used.

Drug Name	Dermatology	Rheumatology
Adalimumab		
Apremilast		
Bimekizumab		
Brodalumab		
Certolizumab Pegol		
Deucravacitinib		
Etanercept		
Etrasimod		
Filgotinib		
Golimumab		
Guselkumab		
Infliximab (Biosimilars)		
Infliximab (Remicade)		
Ixekizumab		
Mirikizumab		
Ozanimod		
Risankizumab		
Secukinumab		
Tildrakizumab		
Tofacitinib		
Upadacitinib		
Ustekinumab		
Vedolizumab		

RESPONSE

Q1. How many patients were treated by individual drug for Plaque Psoriasis and Psoriatic Arthritis for the three-month period specified within Q1a?.

Unable to answer as we don't hold information regarding indications.

Q2a – How many patients were treated with the following drugs from the following departments (for any disease) from the start of January 2026 to the end of March 2026?

Please use the latest available 3 months if January to March is not available and specify which 3 months has been used.

Drug Name	Dermatology	Rheumatology
Adalimumab	122	514
Apremilast	75	<5
Bimekizumab	<5	7
Brodalumab	0	0
Certolizumab Pegol	<5	34
Deucravacitinib	0	0
Etanercept	0	240
Etrasimod	0	0
Filgotinib	0	16
Golimumab	0	42
Guselkumab	35	10
Infliximab (Biosimilars)	0	20
Infliximab (Remicade)	0	0
Ixekizumab	15	7
Mirikizumab	0	0
Ozanimod	0	0
Risankizumab	27	<5
Secukinumab	16	86
Tildrakizumab	0	0
Tofacitinib	0	26
Upadacitinib	15	32
Ustekinumab	32	8
Vedolizumab	0	<5